ProMIS Neurosciences (NASDAQ:PMN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Guggenheim in a research report issued to clients and investors on Wednesday,Benzinga reports.
ProMIS Neurosciences Stock Down 4.5 %
Shares of ProMIS Neurosciences stock opened at $0.74 on Wednesday. The stock has a market cap of $24.03 million, a PE ratio of -7.35 and a beta of 0.56. ProMIS Neurosciences has a 12 month low of $0.65 and a 12 month high of $2.61. The business has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.05.
Institutional Trading of ProMIS Neurosciences
Institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. lifted its position in shares of ProMIS Neurosciences by 6.3% in the third quarter. Sphera Funds Management LTD. now owns 1,929,297 shares of the company’s stock worth $2,412,000 after buying an additional 115,084 shares during the last quarter. Allostery Investments LP bought a new position in ProMIS Neurosciences during the fourth quarter valued at about $185,000. Ally Bridge Group NY LLC increased its stake in ProMIS Neurosciences by 50.3% during the third quarter. Ally Bridge Group NY LLC now owns 1,592,605 shares of the company’s stock valued at $1,991,000 after acquiring an additional 533,023 shares during the period. Finally, Great Point Partners LLC bought a new position in ProMIS Neurosciences during the third quarter valued at about $3,488,000. Institutional investors and hedge funds own 50.13% of the company’s stock.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Five stocks we like better than ProMIS Neurosciences
- What Are Dividend Contenders? Investing in Dividend Contenders
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What is a Secondary Public Offering? What Investors Need to Know
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
